Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 6/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069620 | 0.93 | JAK3 (0.44) | CHEK1JAK3JAK2PIK3CDPIK3CA | |
| SCHEMBL4350214 | 0.89 | JAK3 (0.44) | CHEK1JAK3JAK2PIK3CDPIK3CA | |
| SCHEMBL4349670 | 0.89 | CHEK1 (0.46) | CHEK1JAK3JAK2PIK3CDPIK3CA | |
| SCHEMBL4354913 | 0.87 | PIK3CD (0.49) | CHEK1JAK3JAK2PIK3CDPIK3CA | |
| SCHEMBL3075706 | 0.85 | CHEK1 (0.59) | CHEK1JAK3JAK2PIK3CDPIK3CA | |
| SCHEMBL4342337 | 0.84 | CHEK1 (0.48) | CHEK1PIK3CD | |
| SCHEMBL4342574 | 0.84 | CHEK1 (0.45) | CHEK1JAK3JAK2PIK3CDPIK3CA | |
| SCHEMBL14543510 | 0.81 | CHEK1 (0.48) | CHEK1 | |
| SCHEMBL4345507 | 0.80 | BTK (0.41) | CHEK1JAK3JAK2PIK3CDPIK3CA | |
| SCHEMBL4357649 | 0.80 | CHEK1 (0.47) | CHEK1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100226917-A1 | METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-1869052-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106326-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | CHEK1, PDK1, CHEK2 | CHEK1 1/4885JAK3 2752/4885JAK2 1891/4885 |
| US-20100226917-A1 | METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | CHEK1, CHEK2, MCL1 | CHEK1 1/4885JAK3 562/4885JAK2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.